On July 2, 2025, 4D Molecular Therapeutics announced an acceleration of its 4D-150 4FRONT Phase 3 program for wet age-related macular degeneration (wet AMD). The company now anticipates topline data for the 4FRONT-1 trial in the first half of 2027, which is an acceleration from previous guidance of the second half of 2027.
To support these accelerated timelines and manage increased expenses associated with the 4FRONT clinical trials and Biologics License Application (BLA) preparation, 4DMT has streamlined its operations. This strategic realignment includes a workforce reduction impacting approximately 25% of current and planned roles, primarily in early-stage R&D and support functions.
The company expects these workforce reductions to generate annual cash compensation cost savings of approximately $15.0 million. These savings are designed to offset the additional expenses from the accelerated clinical development, thereby maintaining the company's previously guided cash runway into 2028. This strategic move reflects the company's focus on late-stage execution for its most promising pipeline assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.